A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg

Trial Profile

A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms ODESA
  • Most Recent Events

    • 15 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2016.
    • 15 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016.
    • 15 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top